# Schrodinger, Inc. (SDGR) Stock Analysis: Exploring a 94% Potential Upside in Health Information Services

- Link: https://www.directorstalkinterviews.com/schrodinger-inc-sdgr-stock-analysis-exploring-a-94-potential-upside-in-health-information-services/4121246128
- Published: 2026-03-24T11:27:06+00:00
- Author: Madison Wilson

Schrodinger, Inc. (NASDAQ: SDGR), a key player in the healthcare sector, operates
within the health information services industry with a unique approach that marries
technology and drug development. Based in New York, the company has carved out a
niche by leveraging its physics-based computational platform to accelerate the discovery
of novel molecules, not just for drug development but also for materials applications
worldwide.

Currently valued at $876.3 million, Schrodinger’s stock is trading at $11.87, close
to the lower end of its 52-week range of $11.22 to $26.69. The stock’s modest price
change of -0.15 (-0.01%) hints at a period of consolidation, possibly presenting
a ripe opportunity for discerning investors.

One standout aspect of Schrodinger’s financials is the company’s significant potential
upside. Analysts have set a target price range of $13.00 to $32.00, with an average
target of $23.11. This suggests a potential upside of 94.70%, a figure that should
catch the eye of investors looking for growth opportunities in the healthcare sector.
This optimism is further reflected in the analyst ratings, which include seven buy
ratings and two holds, with no sell recommendations.

Schrodinger’s current valuation metrics present a mixed picture. The absence of 
a P/E ratio and other traditional valuation metrics like PEG, Price/Book, and Price/
Sales indicates the company is currently operating at a loss, as underscored by 
its negative EPS of -1.41. However, the forward P/E ratio of -8.60 suggests expectations
of continued financial challenges, yet the presence of robust free cash flow amounting
to nearly $100 million provides a cushion for future investments and operational
stability.

Revenue growth has been sluggish, showing a decline of 1.20%, and return on equity
is negative at -26.29%. These figures suggest that Schrodinger is still investing
heavily in its growth and development phases, particularly in its drug discovery
initiatives. The company’s collaboration with industry giant Novartis Pharma AG 
underscores its strategic focus on expanding its portfolio of preclinical and clinical
programs.

From a technical perspective, Schrodinger’s stock is trading below both its 50-day
and 200-day moving averages of $13.52 and $18.20, respectively. The RSI (14) stands
at 56.07, indicating that the stock is neither overbought nor oversold, potentially
setting the stage for a price movement. The MACD and Signal Line, both negative,
suggest a bearish trend, yet given the stock’s current price and potential upside,
it might attract investors willing to ride out short-term volatility for long-term
gains.

In the absence of dividends, investors in Schrodinger are primarily looking for 
capital appreciation. The company’s zero payout ratio implies a reinvestment strategy
geared towards growth, particularly in its innovative software and drug discovery
segments.

Schrodinger, Inc. represents an intriguing choice in the healthcare sector, especially
for investors with a penchant for tech-driven drug development and computational
innovation. With a significant potential upside and a strategic partnership with
Novartis, Schrodinger is a company to watch, particularly for those willing to navigate
the complexities of its current financial landscape for potential future rewards.

Share on: